קלרידקס

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

CLARITHROMYCIN

Disponível em:

DEXCEL LTD, ISRAEL

Código ATC:

J01FA09

Forma farmacêutica:

קפליות

Composição:

CLARITHROMYCIN 250 MG

Via de administração:

פומי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

DEXCEL LTD, ISRAEL

Grupo terapêutico:

CLARITHROMYCIN

Área terapêutica:

CLARITHROMYCIN

Indicações terapêuticas:

Klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. Indications include: Lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. Upper respiratory tract infections, for example, sinusitis and pharyngitis. Klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. Klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. Klaridex is also indicated in combination with proton pump inhibitor for the eradication of H. Pylori in patients with proven duodenal ulcer. Treatment of Mycobacterium Avium Complex infection in AIDS patients.

Data de autorização:

2014-05-31